DK2808393T3 - Cells insufficient for fucosylation - Google Patents
Cells insufficient for fucosylation Download PDFInfo
- Publication number
- DK2808393T3 DK2808393T3 DK14179885.0T DK14179885T DK2808393T3 DK 2808393 T3 DK2808393 T3 DK 2808393T3 DK 14179885 T DK14179885 T DK 14179885T DK 2808393 T3 DK2808393 T3 DK 2808393T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- cells
- fucosylation
- fucose
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18340009P | 2009-06-02 | 2009-06-02 | |
| US34885810P | 2010-05-27 | 2010-05-27 | |
| EP10721096.5A EP2438171B1 (en) | 2009-06-02 | 2010-06-01 | Fucosylation-deficient cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2808393T3 true DK2808393T3 (en) | 2018-03-12 |
Family
ID=42338231
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14179885.0T DK2808393T3 (en) | 2009-06-02 | 2010-06-01 | Cells insufficient for fucosylation |
| DK10721096.5T DK2438171T3 (en) | 2009-06-02 | 2010-06-01 | Fucosylerings-deficient cells |
| DK17192430.1T DK3279326T3 (da) | 2009-06-02 | 2010-06-01 | Fucosyleringsdeficiente celler |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10721096.5T DK2438171T3 (en) | 2009-06-02 | 2010-06-01 | Fucosylerings-deficient cells |
| DK17192430.1T DK3279326T3 (da) | 2009-06-02 | 2010-06-01 | Fucosyleringsdeficiente celler |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8409838B2 (enExample) |
| EP (3) | EP2438171B1 (enExample) |
| JP (4) | JP5744856B2 (enExample) |
| KR (2) | KR101641526B1 (enExample) |
| CN (1) | CN102459603B (enExample) |
| AU (1) | AU2010256753B2 (enExample) |
| BR (1) | BRPI1010035A2 (enExample) |
| CA (1) | CA2764370C (enExample) |
| DK (3) | DK2808393T3 (enExample) |
| ES (2) | ES2527173T3 (enExample) |
| HU (1) | HUE038596T2 (enExample) |
| IL (1) | IL216624A (enExample) |
| PL (3) | PL2808393T3 (enExample) |
| SG (1) | SG176251A1 (enExample) |
| TW (1) | TWI513818B (enExample) |
| WO (1) | WO2010141478A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140161782A1 (en) | 2008-06-09 | 2014-06-12 | Targazyme, Inc. | Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase |
| DK2808393T3 (en) * | 2009-06-02 | 2018-03-12 | Regeneron Pharma | Cells insufficient for fucosylation |
| CN103597073B (zh) | 2011-03-06 | 2019-06-07 | 默克雪兰诺有限公司 | 低岩藻糖细胞系及其应用 |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2722673B1 (en) | 2012-10-17 | 2017-07-12 | Hexal AG | Improved method of mapping glycans of glycoproteins |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
| US20150093782A1 (en) * | 2013-10-01 | 2015-04-02 | The University Of Wyoming | Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins |
| AU2015229591B2 (en) | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
| WO2015184325A2 (en) * | 2014-05-30 | 2015-12-03 | New England Biolabs, Inc. | Deglycosylation reagents and methods |
| CN114540266A (zh) * | 2014-07-07 | 2022-05-27 | 塔尔加泽梅股份有限公司 | 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥 |
| CN105671109B (zh) * | 2014-11-20 | 2019-08-23 | 中国人民解放军军事医学科学院生物工程研究所 | 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| CN108431026B (zh) * | 2015-11-02 | 2023-02-17 | 豪夫迈·罗氏有限公司 | 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法 |
| JP6674028B2 (ja) * | 2016-01-06 | 2020-04-01 | アウトルック セラピューティクス，インコーポレイティド | モノクローナル抗体組成物中のアフコシル化種の調節 |
| EP3411401A1 (en) | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
| US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| EP3339444A1 (en) * | 2016-12-20 | 2018-06-27 | Mabxience Research, S.L. | Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| WO2020042015A1 (en) * | 2018-08-29 | 2020-03-05 | United Biopharma Inc | Afucosylated antibodies and manufacture thereof |
| EP3875480A4 (en) | 2018-10-29 | 2022-07-13 | Immuno-Biological Laboratories Co., Ltd. | ANTI-HIV ANTIBODIES AND METHODS OF PRODUCTION THEREOF |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| MX2022014598A (es) | 2020-05-26 | 2023-03-31 | Regeneron Pharma | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. |
| CR20220660A (es) | 2020-06-03 | 2023-02-17 | Regeneron Pharma | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 |
| CN112843234B (zh) * | 2021-01-20 | 2022-09-06 | 四川大学华西第二医院 | 一种调控生物机体内gdp-甘露糖的浓度的装置 |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| JP2024527235A (ja) | 2021-06-22 | 2024-07-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ＥＧＦＲｖＩＩＩ抗体薬物コンジュゲート及びその使用 |
| EP4370210A1 (en) | 2021-07-14 | 2024-05-22 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| EP4486778A1 (en) | 2022-03-02 | 2025-01-08 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1006070A (en) | 1909-05-11 | 1911-10-17 | George Walter Durbrow | Method of and means for extracting micro-organisms and solids from water. |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| JP2001145488A (ja) | 1999-11-19 | 2001-05-29 | Natl Inst Of Advanced Industrial Science & Technology Meti | シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子 |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN103333860B (zh) * | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US20020150968A1 (en) | 2001-01-10 | 2002-10-17 | Wang Peng G. | Glycoconjugate and sugar nucleotide synthesis using solid supports |
| ATE325865T1 (de) | 2001-01-16 | 2006-06-15 | Regeneron Pharma | Isolierung von sezernierte proteine exprimierenden zellen |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| KR100585140B1 (ko) | 2004-04-26 | 2006-05-30 | 삼성전자주식회사 | 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법 |
| US20060223147A1 (en) * | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
| KR20080032065A (ko) | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| KR20090130029A (ko) | 2007-03-07 | 2009-12-17 | 글리코파이, 인크. | 푸코실화가 변형된 당단백질의 제조 |
| DK2150617T3 (en) | 2007-06-04 | 2015-01-12 | Regeneron Pharma | Regions with increased expression and stability |
| JP5662149B2 (ja) | 2008-08-13 | 2015-01-28 | 協和発酵キリン株式会社 | 遺伝子組換えプロテインｓ組成物 |
| DK2808393T3 (en) | 2009-06-02 | 2018-03-12 | Regeneron Pharma | Cells insufficient for fucosylation |
| CN103597073B (zh) | 2011-03-06 | 2019-06-07 | 默克雪兰诺有限公司 | 低岩藻糖细胞系及其应用 |
-
2010
- 2010-06-01 DK DK14179885.0T patent/DK2808393T3/en active
- 2010-06-01 EP EP10721096.5A patent/EP2438171B1/en active Active
- 2010-06-01 EP EP17192430.1A patent/EP3279326B1/en active Active
- 2010-06-01 PL PL14179885T patent/PL2808393T3/pl unknown
- 2010-06-01 US US12/791,637 patent/US8409838B2/en active Active
- 2010-06-01 DK DK10721096.5T patent/DK2438171T3/en active
- 2010-06-01 SG SG2011087517A patent/SG176251A1/en unknown
- 2010-06-01 PL PL10721096T patent/PL2438171T3/pl unknown
- 2010-06-01 WO PCT/US2010/036914 patent/WO2010141478A1/en not_active Ceased
- 2010-06-01 KR KR1020147007025A patent/KR101641526B1/ko not_active Expired - Fee Related
- 2010-06-01 TW TW099117652A patent/TWI513818B/zh not_active IP Right Cessation
- 2010-06-01 JP JP2012514045A patent/JP5744856B2/ja not_active Expired - Fee Related
- 2010-06-01 HU HUE14179885A patent/HUE038596T2/hu unknown
- 2010-06-01 BR BRPI1010035-0A patent/BRPI1010035A2/pt not_active Application Discontinuation
- 2010-06-01 ES ES10721096.5T patent/ES2527173T3/es active Active
- 2010-06-01 CA CA2764370A patent/CA2764370C/en active Active
- 2010-06-01 KR KR1020117031320A patent/KR101441437B1/ko not_active Expired - Fee Related
- 2010-06-01 CN CN2010800294912A patent/CN102459603B/zh not_active Expired - Fee Related
- 2010-06-01 AU AU2010256753A patent/AU2010256753B2/en not_active Ceased
- 2010-06-01 DK DK17192430.1T patent/DK3279326T3/da active
- 2010-06-01 EP EP14179885.0A patent/EP2808393B1/en active Active
- 2010-06-01 PL PL17192430T patent/PL3279326T3/pl unknown
- 2010-06-01 ES ES14179885.0T patent/ES2661074T3/es active Active
-
2011
- 2011-11-27 IL IL216624A patent/IL216624A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/779,952 patent/US9206455B2/en active Active
-
2014
- 2014-12-12 JP JP2014251541A patent/JP2015051021A/ja not_active Withdrawn
-
2015
- 2015-12-08 US US14/963,178 patent/US9550823B2/en active Active
-
2016
- 2016-03-07 JP JP2016043151A patent/JP6211642B2/ja not_active Expired - Fee Related
- 2016-10-14 JP JP2016202634A patent/JP2017006147A/ja active Pending
- 2016-12-14 US US15/378,670 patent/US10006070B2/en active Active
-
2018
- 2018-05-23 US US15/987,286 patent/US20190024129A1/en not_active Abandoned
-
2019
- 2019-08-30 US US16/556,334 patent/US20200080124A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,255 patent/US11560550B2/en active Active
-
2022
- 2022-12-15 US US18/066,303 patent/US12054751B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12054751B2 (en) | Fucosylation-deficient cells | |
| AU2015282354B2 (en) | Fucosylation-deficient cells | |
| AU2012100020A6 (en) | Fucosylation-deficient cells | |
| AU2014200152B2 (en) | Fucosylation-deficient cells | |
| HK1249547B (en) | Fucosylation-deficient cells | |
| HK1198180B (en) | Fucosylation-deficient cells | |
| HK1163745B (en) | Fucosylation-deficient cells |